Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial

Journal:

The Lancet

Published:

2026-04-23

DOI:

10.1016/s0140-6736(26)00258-8

Affiliations:

11

Authors:

28

Go to article

Institutions	Authors	Share
Kenya Medical Research Institute (KEMRI), Kenya	9.000000	0.32
NIH NIAID Vaccine Research Center (VRC), United States of America (USA)	6.000000	0.21
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), CDC, United States of America (USA)	3.000000	0.11
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)	3.000000	0.11
NIH NIAID Division of Intramural Research (DIR), United States of America (USA)	2.000000	0.07
Centers for Disease Control and Prevention-Kenya (CDC-K), Kenya	1.000000	0.04
Frederick National Laboratory for Cancer Research (FNLCR), United States of America (USA)	1.000000	0.04
Liverpool School of Tropical Medicine (LSTM), United Kingdom (UK)	1.000000	0.04
UW Medicine, United States of America (USA)	1.000000	0.04
Indiana University Indianapolis (IU Indianapolis), United States of America (USA)	1.000000	0.04

Interested in Medical Microbiology?